Nicolas Boissel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8182389/publications.pdf

Version: 2024-02-01

190 papers	12,851 citations	41323 49 h-index	25770 108 g-index
199 all docs	199 docs citations	199 times ranked	14076 citing authors

#	Article	IF	Citations
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	13.9	3,680
2	Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. Journal of Clinical Oncology, 2003, 21, 774-780.	0.8	552
3	Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 2002, 100, 2717-2723.	0.6	476
4	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosomeâ€“Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 2017, 35, 1795-1802.	0.8	348
5	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, The, 2021, 398, 491-502.	6.3	315
6	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013, 121, 2213-2223.	0.6	313
7	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	0.6	281
8	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 1044-1053.	13.9	270
9	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012, 120, 4317-4323.	0.6	247
10	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood, 2018, 131, 717-732.	0.6	240
11	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	0.8	227
12	Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood, 2005, 106, 3618-3620.	0.6	208
13	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet, The, 2020, 396, 1885-1894.	6.3	206
14	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	0.6	198
15	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
16	Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. Journal of Experimental Medicine, 2010, 207, 731-750.	4.2	169
17	High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood, 2009, 113, 5583-5587.	0.6	162
18	Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica, 2013, 98, e146-e148.	1.7	157

#	Article	IF	Citations
19	Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood, 2019, 134, 1441-1444.	0.6	153
20	NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood, 2009, 113, 1730-1740.	0.6	150
21	Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertility and Sterility, 2021, 115, 1102-1115.	0.5	145
22	Early Responseâ€"Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2017, 35, 2683-2691.	0.8	134
23	BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia. Journal of Immunology, 2006, 176, 5108-5116.	0.4	126
24	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. Journal of Clinical Oncology, 2009, 27, 4747-4753.	0.8	123
25	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135.	0.6	121
26	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	1.3	106
27	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124, 1445-1449.	0.6	105
28	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. Journal of Clinical Oncology, 2018, 36, 2514-2523.	0.8	99
29	Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica, 2016, 101, 328-335.	1.7	97
30	Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leukemia and Lymphoma, 2012, 53, 1352-1359.	0.6	93
31	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	0.8	92
32	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood, 2019, 134, 1351-1355.	0.6	89
33	The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood, 2009, 113, 5090-5093.	0.6	87
34	Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. Blood, 2018, 132, 351-361.	0.6	82
35	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia, 2021, 35, 3383-3393.	3.3	77
36	Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia. Cancer, 2009, 115, 3719-3727.	2.0	75

#	Article	IF	Citations
37	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 555-573.	1.8	71
38	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	0.8	68
39	Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. Journal of Immunology, 2015, 195, 2580-2590.	0.4	68
40	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	5.1	65
41	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood, 2020, 135, 542-546.	0.6	62
42	Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 221-221.	0.6	62
43	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood, 2014, 124, 1312-1319.	0.6	61
44	Treatment of Refractory Erdheimâ€“Chester Disease with Double Autologous Hematopoietic Stem-Cell Transplantation. Annals of Internal Medicine, 2001, 135, 844.	2.0	59
45	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood, 2018, 132, 187-196.	0.6	54
46	Oxidative Stress Mediates a Reduced Expression of the Activating Receptor NKG2D in NK Cells from End-Stage Renal Disease Patients. Journal of Immunology, 2009, 182, 1696-1705.	0.4	53
47	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, 1754-1762.	0.6	52
48	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica, 2015, 100, 898-904.	1.7	52
49	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood, 2011, 118, 5099-5107.	0.6	50
50	Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leukemia and Lymphoma, 2012, 53, 1068-1076.	0.6	50
51	Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. European Journal of Immunology, 2014, 44, 3068-3080.	1.6	49
52	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances, 2020, 4, 1942-1949.	2.5	49
53	Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. Journal of Adolescent and Young Adult Oncology, 2015, 4, 118-128.	0.7	48
54	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood, 2019, 133, 280-284.	0.6	48

#	Article	IF	Citations
55	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 2014, 5, 916-932.	0.8	47
56	Neurofibromatosisâ€1 gene deletions and mutations in de novo adult acute myeloid leukemia. American Journal of Hematology, 2013, 88, 306-311.	2.0	43
57	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematology,the, 2021, 8, e355-e364.	2.2	43
58	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica, 2015, 100, 780-785.	1.7	42
59	Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells. Cellular Microbiology, 2007, 9, 1412-1425.	1.1	40
60	Pediatric-Like Therapy for Adults with ALL. Current Hematologic Malignancy Reports, 2014, 9, 158-164.	1.2	40
61	DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, 1617-1625.	1.7	40
62	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138, 507-519.	0.6	40
63	Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies. Haematologica, 2019, 104, e360-e363.	1.7	38
64	Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2011, 117, 3696-3697.	0.6	36
65	Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica, 2018, 103, 822-829.	1.7	36
66	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosomeâ€“positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. European Journal of Cancer, 2021, 146, 107-114.	1.3	36
67	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 2281-2288.	0.6	35
68	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood, 2021, 137, 524-532.	0.6	33
69	Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. Current Opinion in Hematology, 2009, 16, 92-97.	1.2	30
70	Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators. Experimental Hematology, 2017, 51, 7-16.	0.2	29
71	Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study. Blood, 2015, 126, 1-1.	0.6	29
72	Contribution of <scp>CD</scp>39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. British Journal of Haematology, 2014, 165, 722-725.	1.2	26

#	Article	IF	Citations
73	Epigenetic Silencing Affects<scp>l</scp>-Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research, 2019, 25, 2483-2493.	3.2	25
74	Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica, 2011, 96, 837-844.	1.7	24
75	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. European Journal of Cancer, 2014, 50, 1159-1168.	1.3	24
76	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweetâ€™s Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. Journal of Investigative Dermatology, 2020, 140, 1873-1876.e5.	0.3	23
77	PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. Blood, 2021, 138, 1855-1869.	0.6	23
78	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1â€RUNX1T1 fusion quantification on genomic DNA. American Journal of Hematology, 2014, 89, 610-615.	2.0	21
79	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia, 2020, 34, 1730-1740.	3.3	21
80	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. Journal of Clinical Oncology, 2015, 33, 3065-3065.	0.8	21
81	A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2021, 138, 740-740.	0.6	21
82	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. International Journal of Molecular Sciences, 2020, 21, 5626.	1.8	20
83	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. Journal of Translational Medicine, 2021, 19, 265.	1.8	20
84	Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. Journal of Leukocyte Biology, 2006, 79, 747-756.	1.5	19
85	A new pattern of cytosineâ€arabinosideâ€induced lung toxicity. British Journal of Haematology, 2009, 147, 771-774.	1.2	19
86	The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. Blood, 2009, 114, 4601-4602.	0.6	19
87	UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	0.6	19
88	Graft-Versus-Host Disease in Adolescents and Young Adults (15â€“24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission. Journal of Adolescent and Young Adult Oncology, 2017, 6, 299-306.	0.7	19
89	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia, 2018, 32, 2008-2081.	3.3	18
90	Value of EVI1 Gene Expression Level in Adult Acute Lymphoblastic Leukemia (ALL): A Study from the Group for Research on Adult ALL (GRAALL). Blood, 2014, 124, 1081-1081.	0.6	18

#	Article	IF	Citations
91	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica, 2015, 100, e196-e199.	1.7	16
92	Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blastâ€phase myeloproliferative neoplasms. British Journal of Haematology, 2016, 172, 628-630.	1.2	16
93	Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival. Journal of Adolescent and Young Adult Oncology, 2021, 10, 29-45.	0.7	16
94	Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2034-2041.	3.3	15
95	Adolescents and young adults with cancer: How multidisciplinary health care teams adapt their practices to better meet their specific needs. Psycho-Oncology, 2019, 28, 1576-1582.	1.0	15
96	Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation. Journal of Experimental Medicine, 2020, 217, .	4.2	15
97	Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22 â€positive Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, e53-e56.	1.2	15
98	SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget, 2018, 9, 6478-6489.	0.8	15
99	p16INK4A tumor suppressor gene expression and CD3Ïµ deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis. Blood, 2007, 110, 2610-2619.	0.6	14
100	Diagnosis of Ureaplasma urealyticum Septic Polyarthritis by PCR Assay and Electrospray Ionization Mass Spectrometry in a Patient with Acute Lymphoblastic Leukemia: FIG 1. Journal of Clinical Microbiology, 2014, 52, 3456-3458.	1.8	14
101	Impact of the source of hematopoietic stem cell in unrelated transplants: Comparison between 10/10, 9/10â€<scp>HLA</scp> matched donors and cord blood. American Journal of Hematology, 2015, 90, 897-903.	2.0	14
102	Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Science Translational Medicine, 2021, 13, .	5.8	13
103	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. Blood, 2016, 128, 762-762.	0.6	13
104	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 372-372.	0.6	13
105	Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood, 2022, 139, 3505-3518.	0.6	13
106	Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. Oncotarget, 2017, 8, 80073-80082.	0.8	12
107	Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial. Blood Cancer Journal, 2018, 8, 45.	2.8	12
108	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1981-1988.	2.5	12

#	Article	IF	Citations
109	Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.. Blood, 2006, 108, 147-147.	0.6	12
110	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Advances, 2021, 5, 5258-5268.	2.5	12
111	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	0.6	12
112	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. British Journal of Haematology, 2018, 183, 766-774.	1.2	11
113	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2020, 105, 1575-1581.	1.7	10
114	EHA evaluation of the ESMOâ€"Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open, 2020, 5, e000611.	2.0	10
115	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia, 2021, 35, 712-723.	3.3	10
116	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. Journal of Hematology and Oncology, 2021, 14, 74.	6.9	10
117	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). Blood, 2012, 120, 3561-3561.	0.6	10
118	Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study. Blood, 2021, 138, 511-511.	0.6	10
119	Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2. Blood, 2021, 138, 1232-1232.	0.6	10
120	Isatuximab monotherapy in patients with refractory Tâ€acute lymphoblastic leukemia or Tâ€lymphoblastic lymphoma: Phase 2 study. Cancer Medicine, 2022, 11, 1292-1298.	1.3	10
121	High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.. Haematologica, 2022, , .	1.7	10
122	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 2012, 36, 1112-1118.	0.4	9
123	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.4	9
124	Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience. Blood, 2019, 134, 3876-3876.	0.6	9
125	The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study. Blood, 2021, 138, 512-512.	0.6	9
126	How should we treat the AYA patient with newly diagnosed ALL?. Best Practice and Research in Clinical Haematology, 2017, 30, 175-183.	0.7	8

#	Article	IF	Citations
127	IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL. Blood, 2021, 137, 1690-1694.	0.6	8
128	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. Leukemia, 2021, 35, 724-736.	3.3	8
129	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica, 2021, 106, 1767-1769.	1.7	8
130	Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis. Leukemia and Lymphoma, 2020, 61, 737-740.	0.6	7
131	Can Some Anticancer Treatments Preserve the Ovarian Reserve?. Oncologist, 2021, 26, 492-503.	1.9	7
132	TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML). Leukemia Research, 2017, 56, 21-28.	0.4	6
133	Tolerance to arsenic trioxide combined with allâ€transâ€retinoic acid in children with acute promyelocytic leukaemia in France. British Journal of Haematology, 2020, 188, 170-173.	1.2	6
134	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. Journal of the American Academy of Dermatology, 2020, 83, 1166-1170.	0.6	6
135	BCR/ABL Oncogene Controls MICA Translation.. Blood, 2005, 106, 4389-4389.	0.6	6
136	A multiparametric niche-like drug screening platform in acute myeloid leukemia. Blood Cancer Journal, 2022, 12, .	2.8	6
137	ALL in escape room. Blood, 2021, 137, 432-434.	0.6	5
138	Minimal Residual Disease At 3 Months, Combined to the Presence of IKZF1 Deletion in B-Lineage or Absence of NOTCH1 pathway Mutation in T-Lineage, Recapitulates the Disease Risk Assessment in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia - A GRAALL Study. Blood, 2011, 118, 572-572.	0.6	5
139	Optimizing use of L-asparaginaseâ€“based treatment of adults with acute lymphoblastic leukemia. Blood Reviews, 2022, 53, 100908.	2.8	5
140	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. Modern Pathology, 2022, 35, 1227-1235.	2.9	5
141	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. Annals of Hematology, 2015, 94, 1859-1863.	0.8	4
142	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 2020, 12, 88.	1.7	4
143	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. Blood, 2019, 134, 1295-1295.	0.6	4
144	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 163-163.	0.6	4

#	Article	IF	Citations
145	Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study. Blood, 2016, 128, 2776-2776.	0.6	4
146	Incidence and Prognosis of RTKs and RAS Mutations in CBF AML. A Retrospective Study of French Adult ALFA and Pediatric LAME Trials.. Blood, 2004, 104, 2022-2022.	0.6	4
147	Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. Open Forum Infectious Diseases, 2022, 9, ofac088.	0.4	4
148	Dysfunction of Phrenic Pacemakers Induced by Metallic Rescue Blankets. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 241-243.	0.5	3
149	Novel Intergenically Spliced Chimera, NFATC3-PLA2G15, Is Associated with Aggressive T-ALL Biology and Outcome. Molecular Cancer Research, 2018, 16, 470-475.	1.5	3
150	T-Cell Acute Lymphoblastic Leukemia in a Young Adult With Thrombocytopenia-absent Radius Syndrome: A Case Report and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2021, 43, 232-235.	0.3	3
151	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. Blood, 2021, 138, 3478-3478.	0.6	3
152	Immunotherapies in acute leukemia. Therapie, 2022, 77, 241-250.	0.6	3
153	Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e199-e205.	0.2	2
154	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. Blood, 2018, 132, 993-993.	0.6	2
155	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 4440-4440.	0.6	2
156	Treatment of Acute Lymphoblastic Leukemia in Young Adults. , 2011, , 211-232.		1
157	Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC). Blood, 2019, 134, 2700-2700.	0.6	1
158	Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study. Blood, 2019, 134, 5130-5130.	0.6	1
159	Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.. Blood, 2008, 112, 1934-1934.	0.6	1
160	Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse. Blood, 2011, 118, 2603-2603.	0.6	1
161	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327.	0.6	1
162	Prognostic Impact of Wilms Tumor 1 Single Nucleotide Polymorphism rs16754 In Older Patients with Acute Myeloid Leukemia. Blood, 2010, 116, 2701-2701.	0.6	1

#	Article	IF	Citations
163	NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group. Blood, 2015, 126, 2581-2581.	0.6	1
164	Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. Blood, 2019, 134, 2627-2627.	0.6	1
165	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. Blood, 2019, 134, 2624-2624.	0.6	1
166	Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study. Blood, 2021, 138, 215-215.	0.6	1
167	Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. PLoS ONE, 2022, 17, e0270744.	1.1	1
168	Place deÂlaÂbiologie molÃ©culaire dansÂlâ€™Ã©valuation pronostique desÂpatients atteints deÂleucÃ©mie aiguÃ« myÃ©loÃ¯de. Hematologie, 2009, 15, 426-443.	0.0	0
169	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. Hematologie, 2011, 17, 132-144.	0.0	0
170	Should young adults with ALL be treated as children?. Blood, 2019, 133, 1519-1520.	0.6	0
171	Autologous Hematopoietic Stem Cell Collection and Transplantation in Acute Myeloid Leukemia Patients in Second Remission after Treatment with Fractionated Gentuzumab Ozogamycin.. Blood, 2006, 108, 5211-5211.	0.6	0
172	Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.. Blood, 2007, 110, 3496-3496.	0.6	0
173	Incidence and Prognostic Impact of SNPs Regulating PU.1 Gene Expression in AML. Blood, 2008, 112, 2949-2949.	0.6	0
174	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50 Years: a Retrospective Single Center Study. Blood, 2008, 112, 3309-3309.	0.6	0
175	A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age. Blood, 2010, 116, 2125-2125.	0.6	0
176	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. Blood, 2010, 116, 4171-4171.	0.6	0
177	Early Admission to the Intensive Care Unit In High Risk Acute Myeloid Leukemia Patients. Blood, 2010, 116, 4364-4364.	0.6	0
178	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. Blood, 2011, 118, 410-410.	0.6	0
179	Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients. Blood, 2013, 122, 2657-2657.	0.6	0
180	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. Blood, 2013, 122, 1353-1353.	0.6	0

#	Article	IF	Citations
181	Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3723-3723.	0.6	0
182	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. Blood, 2014, 124, 2360-2360.	0.6	0
183	Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia: On Behalf of Eurocord, Ctiwp and PDWP of EBMT. Blood, 2018, 132, 3369-3369.	0.6	0
184	Minimal Residual Disease in Ovarian Biopsies Collected in Patients with Bone Marrow Complete Remission of Acute Lymphoblastic Leukemia. Blood, 2018, 132, 916-916.	0.6	0
185	Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort. Blood, 2018, 132, 1537-1537.	0.6	0
186	A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia. Blood, 2019, 134, 2511-2511.	0.6	0
187	Semen Cryopreservation in Adolescents and Young Adults with Hematologic Diseases: from Bed to Benchside. Journal of Adolescent and Young Adult Oncology, 2021, , .	0.7	0
188	HLA-Matched Related Hematopoietic Stem Cell Transplantation in Adolescents and Adults with Sickle Cell Disease: Comparison of Myeloablative Versus Non Myeloablative Approaches. Report from the SociÃ©tÃ© Francophone De Greffe De Moelle Et De ThÃ©rapie Cellulaire. Blood, 2021, 138, 909-909.	0.6	0
189	Early Immune Reconstitution after Hematopoietic Stem Cell Transplantation for Adolescents and Adults with Sickle Cell Disease. Blood, 2021, 138, 3907-3907.	0.6	0
190	Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis. Blood, 2020, 136, 35-36.	0.6	0